Biologics in the treatment of rheumatoid arthritis and ankylosing spondylitis

J. Braun[1] and J.R. Kalden[2]

[1]*Rheumazentrum Ruhrgebiet, Herne, Germany.*
[2]*Abteilung für Molekulare Immunologie, Nikolaus-Fiebiger-Zentrum, Erlangen, Germany.*

Jürgen Braun, MD, Professor
Joachim Robert Kalden, MD, Professor

Please address correspondence to:
Prof. Jürgen Braun,
Rheumazentrum Ruhrgebiet
Landgrafenstraße 15,
44652 Herne, Germany.
J.Braun@rheumazentrum-ruhrgebiet.de

Received and accepted on July 30, 2009.

Clin Exp Rheumatol 2009; 27 (Suppl. 55): S164-S167.

© Copyright CLINICAL AND EXPERIMENTAL RHEUMATOLOGY 2009.

Key words: anti-TNF-α, anti-interleukin-6 receptor, CTLA4-Ig, B cells.

Conflict of interest: DR J.R. Kalden serves as a consultant to Wyeth; Dr J. Braun has declared no competing interests

.**ABSTRACT**

There are clear differences in the clinical picture and in the pathogenesis between rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Biologic agents targeting TNF-α are efficacious in both diseases, with some tendency to work even better in spondyloarthritides (SpA) on a clinical basis. However, anti-TNF therapy was shown to inhibit radiographic progression in RA but not in AS. This is probably due to the outstanding difference in pathogenesis: while in RA osteodestructive lesions such as erosions predominate, AS patients will rather develop osteoproliferative changes such as syndesmophytes. There is some evidence that anti-TNF agents may show longterm efficacy and acceptable safety profiles over 5–10 years. There are some differences between the agents.

Whether the recent developments of targeted therapies in RA with agents such as rituximab, abatacept and tocilizumab will also work for AS is unknown at present.

The differences in the clinical picture and in the pathogenesis between rheumatoid arthritis (RA) and ankylosing spondylitis (AS) have been adressed elsewhere in this supplement. With respect to therapeutic strategies, there are also and especially differences in the affected structures: while the synovium is a critical target in RA, it is rather the bone and the entheses in AS. The axial skeleton is the most important musculoskeletal structure in AS, in RA involvement of many joints of the hand and feet is most characteristic.

Clearly, the treatment options for RA and AS have experienced significant changes over the past decade. However, it needs to be stressed that conventional DMARDs and systemic corticosteroids work differently in RA and AS. NSAIDs are first choice in the treatment of AS but only adjuvants in RA. Thus, the efficacy of biologic therapy is relatively more important in the management of AS. First comparisons in registries indicate a better efficacy and retention rates in AS (1, 2). However, a central problem in these comparisons is the different dosage of infliximab in RA (3mg/kg) *vs*. AS (5mg/kg). On the other hand, there is much more information available in RA since many more agents are approved, many more studies have been conducted, and more data are therefore provided.

The importance of TNF-α as a centrally important cytokine in the pathogenesis of RA and AS has been stressed by experimental data showing the down-regulation of IL-1 and other pro-inflammatory cytokines by infliximab in in vitro synovial cell cultures (3), the up-regulation of TNF-α and TNF-α receptors in the rheumatoid synovium (4) and in the sacroiliac joints (5, 6), and the improvement of arthritis by TNF blockers in animal models even in established disease (7, 8).

Subsequently, an initial open-label and later randomized placebo-controlled trial using infliximab as a single agent in RA, demonstrated a significant and substantial improvement of signs and symptoms of rather severely affected patients (9, 10). When other anti-TNF agents such as etanercept and adalimumab were tested in clinical trials in RA patients, it soon became clear that TNF antagonists were especially more effective when combined with the established 'anchor' DMARD methotrexate (11-13). More recently, it was demonstrated that other combinations of biologics with DMARDs are also efficacious in treating RA (14, 15).

Again, the situation is different in AS: DMARDs and specifically methotrexate do not show any, and this includes no additional effect, on axial symptoms of AS patients (16-18). Whether DMARDs, alone or in combination

with biologics are more efficacious in peripheral arthritis is a matter of ongoing discussion.

TNF blockers were shown to inhibit radiographic progression in RA (19, 20). Recent observations in RA patients being treated with infliximab showed a dissociation between the (absent) clinical response and a definite inhibition of radiographic progression, this phenomenon is as yet not completely understood (21).

Again, the situation in AS is completely different. One problem is that there are no placebo controlled trials – therefore, a historical cohort (OASIS) was used for comparisons (22, 23). The other one is that in contrast to RA where osteodestructive changes are seen we are dealing with osteoproliferative changes and new bone formation in AS. Using the radiographic scoring system mSASSS to quantify radiographic structural changes in AS patients treated with TNF blockers no influence on radiographic progression after 2 years and 4 years was observed (24).

The treatment of AS patients with TNF antagonists was first performed in Berlin. Initially infliximab was used (24), later etanercept (26), and finally adalimumab (27) and golimumab (28). After the pilot study (29) a national multicenter investigator driven trial was conducted that demonstrated a significant improvement of disease activity, function, spinal mobility and quality of life in comparison to controls (24), this study was the basis of approval of infliximab for active AS in Europe. All following studies showed the same: a persistent clinical response with an acceptable safety profile (30-32). Similar data with TNF antagonists were obtained in RA (33, 34).

Discontinuation of anti-TNF therapy in an established clinical situation, even in patients in clinical remission, was usually be followed by a flare of the disease (35). However, single patients may stay in remission for longer periods of time (36).

The influence on other disease manifestations of SpA such as uveitis and colitis associated with chronic inflammatory bowel diseases has also been tested, some differences between the agents were reported (37, 38).

Fig. I. A systematic comparison between rheumatoid arthritis and ankylosing spondylitis – therapy with biologics.

	RA established	AS established	RA early	AS/SpA early
Anti-TNF therapy				
Infliximab	+++	+++	+++	+++
Etanercept	+++	+++	+++	ND
Adalimumab	+++	+++	+++	+++
Golimumab	+++	+++		ND
Certolizumab	+++	ND	ND	ND
Anti-B-cell therapy				
Rituximab	++	(+) ?	ND	ND
Ofatumumab	++	ND	ND	ND
Anti-BAFF	+	ND	ND	ND
Anti-T-cell therapy				
Anti-CD 4	+	ND	ND	ND
Abatacept	++	study ongoing	ND	ND
Anti-IL-1 therapy				
Anakinra	+	(-) ?	ND	ND
Anti-IL-6 therapy				
Tocilizumab	+++	ND	+++	ND

TNF antagonists such as adalimumab may even reduce signs and symptoms of patients with active AS with total spinal ankylosis (39). However, it is also clear that older age, longer disease duration, more structural damage and decreased function are associated with poorer responses to anti-TNF therapy (40).

Nevertheless, the other end of the spectrum deserves even more interest.

In RA the importance of early and intensive therapy, tight control and rapid adaptations of therapy if necessary are supported by an number of carefully conducted trials, and this was shown with and without biologics (42-46).

In contrast, in AS the time to diagnosis is still in the range of several years. However, two recent studies have been conducted in early disease (47, 48). The classification and diagnosis of early axial spondyloarthritis has recently been facilitated by validation of a new criteria set that includes MRI and x-rays as important imaging tools and HLA B27 in the absence of that evidence (49). On the basis of the new treatment paradigm of early 'aggressive' therapy, adalimumab and infliximab were effective to reduce clinical and imaging evidence of increased disease activity in patients with early axial spondyloarthritis as determined by MRI (47, 48).

Clinical experience tells that a significant proportion of patients do not respond to TNF antagonists (primary non-response) or efficacy is lost over time (secondary non-response). This is the clinical situation when the question of switching to another TNF blocker or a different biologic comes into place. RA patients who failed one TNF antagonist or even a second one may still be successfully treated with another one (50-52). Similar data have also been obtained in AS patients (53, 54), However, for both diseases placebo-controlled trials are needed before definite conclusions can be drawn.

All three TNF antagonists might exhibit some immunogeneicity. This has been specifically reported for the chimeric antibody infliximab but also for adalimumab, less so for etanercept (55). Therefore, one of the reasons why a combination of TNF antagonists with DMARDs such as methotrexate may be superior with regard to clinical efficacy as compared to monotherapy, could be the suppression of human anti-chimeric or anti-infliximab antibodies (HACAs or AIAs). The overall percentage of patients developing antibodies seems to be rather small. Although combination therapy is of no proven benefit for AS patients, it is of interest whether such antibodies influence clinical efficacy. Indeed, it was recently shown that in AS high levels of serum trough infliximab showed some correlation to the clinical response (56). However, another study reported a highly heterogeneous

responsiveness to anti-TNF treatment among individual AS patients and low or high circulating infliximab concentrations rather failed to explain treatment success or failure (57).

New TNF-α inhibitors have recently been introduced into the treatment of RA: Golimumab, a human anti-TNF monoclonal antibody (58), Certolizumab pegol, a PEGylated tumor necrosis factor inhibitor (59), and furthermore, Tocilizumab, a humanized antibody against the IL-6 receptor (60). Tocilizumab has even worked better than methotrexate in RA when these drugs were compared as monotherapies (61). The latter two have not yet been tested in treatment trials with AS patients. The only non anti-TNF biologic that has been tested in AS to date was anakinra (62,63) which did not work very well.

Similarly, B or T cell targeted therapies, which have been successfully applied in RA patients (64, 65) have not yet been used in trials in AS patients.

With regard to the anti-inflammatory activity, there are no major differences using TNF antagonists in both diseases. There are some signals from the clinical trials that infliximab might be used in AS patients with higher doses as in RA to achieve acceptable clinical responses. Likewise, in both diseases a comparable and acceptable safety profile has been observed even over long treatment periods. Differences might exist regarding the risk of tuberculosis and the appearance of HAMAs and HAQAs especially in patients on monotherapy with the monoclonal anti-TNF antibodies.

Applying early and intensive therapy, tight control and rapid adaptations of therapy are necessary. The treatment goal in AS should be similar as for RA to go for remission of the disease. For RA it was shown, for AS it still seems possible to prevent structural damage if therapy starts early enough.

References

1. HEIBERG MS, NORDVÅG BY, MIKKELSEN K *et al.*: The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. *Arthritis Rheum* 2005; 52: 2506-12.
2. HEIBERG MS, KOLDINGSNES W, MIKKELSEN K *et al.*: The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. *Arthritis Rheum* 2008; 59: 234-40
3. BRENNAN FM, CHANTRY D *et al.*: Inhibitory effect of TNFalpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis. *Lancet* 1989; ii: 244.
4. BRENNAN FM, GIBBONS D *et al.*: TNFalpha and TNF receptor expression and regulation in rheumatoid arthritis. *In*: BALINT G, GOMOR B, HODINKA L (Eds.): *Rheumatology, State of the Art*. Amsterdam, Elsevier Science 1997, p 115.
5. BRAUN J *et al.*: Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. *Arthritis Rheum* 1995; 38: 499-505.
6. FRANÇOIS RJ, NEURE L, SIEPER J, BRAUN J: Immunohistological examination of open sacroiliac biopsies of patients with ankylosing spondylitis: detection of tumour necrosis factor alpha in two patients with early disease and transforming growth factor beta in three more advanced cases. *Ann Rheum Dis* 2006; 65: 713-20.
7. KEFFER J, PROBERT L *et al.*: Transgenic mice expressing human tumor necrosis factor: A predictive genetic model of arthritis. *EMBO* 1991; 10: 4025.
8. WILLIAMS RO, FELDMANN M *et al.*: Anti- tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. *Proc Natl Acad Sci USA* 1992; 89: 9784.
9. ELLIOT MJ, MAINI RN *et al.*: Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha. *Arthritis Rheum* (1993); 36: 1681.
10. ELLIOT MJ, MAINI RN *et al.*: Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor alpha versus placebo in rheumatoid arthritis. *Lancet* 1994; 344: 1105.
11. LIPSKY P, VAN DER HEIJDE D *et al.*: Infliximab and methotrexate in the treatment of rheumatoid arthritis: anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy group. *N Engl J Med* 2000; 343: 1594-602.
12. BREEDVELD FC, WEISMAN MH *et al.*: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methorexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum* 2006; 54: 26-37.
13. KLARESKOG L, VAN DER HEIJDE D *et al.*: Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. *Lancet* 2004; 363: 675-81.
14. BURMESTER GR, MARIETTE X *et al.*: Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the research in active rheumatoid arthritis (ReAct) trial. *Ann Rheum Dis* 2007; 66: 732-9.
15. KALDEN JR, NÜSSLEIN HG, WOLLENHAUPT J, BURMESTER GR, KRÜGER K, ANTONI C: Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. *Clin Exp Rheumatol* 2008; 26: 834-40.
16. HAIBEL H *et al.*: No efficacy of subcutaneous methotrexate in active ankylosing spondylitis: a 16-week open-label trial. *Ann Rheum Dis* 2007; 66: 419-21.
17. BREBAN M *et al.*: Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. *Arthritis Rheum* 2008 Jan; 58: 88-97.
18. LI EK *et al.*: Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. *Rheumatology* (Oxford). 2008 Sep; 47: 1358-63. Epub 2008 Jun 23.
19. MAINI RN, BREEDVELD FC *et al.*: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum* 2004; 50: 1051-65.
20. VAN DER HEIJDE D, KLARESKOG L *et al.*: Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis Rheum* 2006; 54: 1063-74.
21. SMOLEN JS, HAN C, BALA M *et al.*: Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. *Arthritis Rheum* 2005; 52: 1020-30.
22. VAN DER HEIJDE D, LANDEWÉ R, EINSTEIN S *et al.*: Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. *Arthritis Rheum* 2008; 58: 1324-31.
23. VAN DER HEIJDE D *et al.*: Radiographic findings following two years of infliximab therapy in patients with ankylosing spondylitis. *Arthritis Rheum* 2008 ; 58: 3063-70.
24. BARALIAKOS X, LISTING J, BRANDT J *et al.*: Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. *Rheumatology* (Oxford). 2007; 46: 1450-3.
25. BRAUN J, BRANDT J *et al.*: Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicenter trial. *Lancet* 2002; 359: 1187-93.
26. DAVIS JC JR, VAN DER HEIJDE D, BRAUN J *et al.*: Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. *Arthritis Rheum* 2003; 48: 3230-6.
27. VAN DER HEIJDE D, KIVITZ A, SCHIFF MH *et al.*: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of

a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum* 2006; 54: 2136-46.
28. INMAN RD, DAVIS JC JR, HEIJDE D *et al.*: Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. *Arthritis Rheum* 2008; 58: 3402-12.
29. BRANDT J, HAIBEL H, CORNELY D *et al.*: Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. *Arthritis Rheum* 2000; 43: 1346-52.
30. BARALIAKOS X *et al.*: Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. *Arthritis Rheum* 2005; 53: 856-63.
31. VAN DER HEIJDE D, SCHIFF MH *et al.*: Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. *Ann Rheum Dis* 2009; 68: 922-30.
32. BRAUN J, BARALIAKOS X *et al.*: Persistent clinical efficacy and safety of anti-tumor necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. *Ann Rheum Dis* 2008; 67: 340-5.
33. WEINBLATT ME, KEYSTONE EC *et al.*: Long-term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. *Ann Rheum Dis* 2006; 65: 753-9.
34. SMOLEN JS, HAN C *et al.*: Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. *Ann Rheum Dis* 2009; 68: 823-8.
35. BARALIAKOS X *et al.*: Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. *Arthritis Res Ther* 2005; 7: R439-44.
36. BARALIAKOS X *et al.*: Safety and efficacy of readministration of infliximab after long-term continuous therapy and withdrawal in patients with ankylosing spondylitis. *J Rheumatol* 2007; 34: 510-5.
37. BRAUN J *et al.*: Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. *Arthritis Rheum* 2005; 52: 2447-51.
38. BRAUN J, BARALIAKOS X, LISTING J *et al.*: Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. *Arthritis Rheum* 2007; 57: 639-47.
39. VAN DER HEIJDE D, PANGAN AL, SCHIFF MH *et al.*: Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. *Ann Rheum Dis* 2008; 67: 1218-21. Epub 2007 Dec 4.
40. RUDWALEIT M, SCHWARZLOSE S, HILGERT ES, LISTING J, BRAUN J, SIEPER J: MRI in predicting a major clinical response to anti-tumour necrosis factor treatment in ankylosing spondylitis. *Ann Rheum Dis* 2008; 67: 1276-81.
41. GRIGOR C, CAPELL H *et al.*: Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. *Lancet* 2004; 364: 263-9.
42. GOEKOOP-RUITERMAN YP, DE VRIES-BOUWSTRA JK *et al.*: Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. *Ann Intern Med* 2007; 146: 406-15.
43. VERSTAPPEN SM, JACOBS JW *et al.*: Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis* 2007; 66: 1443-9.
44. EMERY P, BREEDVELD FC *et al.*: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. *Lancet* 2008; 372: 375-82.
45. GOEKOOP-RUITERMAN YP, DE VRIES-BOUWSTRA JK *et al.*: Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. *Arthritis Rheum* 2005; 52: 3381-90.
46. MOTTONEN T, HANNONEN P *et al.*: Comparison of combination therapy with single drug therapy in early rheumatoid arthritis: a randomized trial. FINACo trial group. *Lancet* 1999; 353: 1568-73.
47. HAIBEL H *et al.*: Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. *Arthritis Rheum* 2008; 58: 1981-91.
48. BARKHAM N, KEEN HI, COATES LC *et al.*: Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. *Arthritis Rheum* 2009; 60: 946-54.
49. RUDWALEIT M *et al.*: The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis* 2009; 68: 777-83.
50. VAN VOLLENHOVEN R, HARJU A *et al.*: Treatment with infliximab (remicade) when etanercept (enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. *Ann Rheum Dis* 2003; 62: 1195-8.
51. VAN VOLLENHOVEN RF: Switching between anti-tumor necrosis factors: trying to get a handle on a complex issue. *Ann Rheum Dis* 2007; 66: 849-51.
52. KEYSTONE EC: Switching tumor necrosis factor inhibitors: an opinion. *Nat Clin Pract Rheumatol* 2006; 2: 576-7.
53. COATES LC, CAWKWELL LS, NG NW *et al.*: Real life experience confirms sustained response to long-term biologics and switching in ankylosing spondylitis. *Rheumatology* (Oxford). 2008; 47: 897-900.
54. PRADEEP DJ, KEAT AC, GAFFNEY K, BROOKSBY A, LEEDER J, HARRIS C: Switching anti-TNF therapy in ankylosing spondylitis. *Rheumatology* (Oxford). 2008; 47: 1726-7.
55. DE VRIES MK, VAN DER HORST-BRUINSMA IE, NURMOHAMED MT *et al.*: Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009; 68: 531-5.
56. DE VRIES M, WOLBINK GJ *et al.*: Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. *Ann Rheum Dis* 2007; 66: 1252-4.
57. KRYZSIEK R, BREBAN M *et al.*: Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. *Arthritis Rheum* 2009; 61: 569-76.
58. KEYSTONE EC, GENOVESE MC *et al.*: Golimumab, a human antibody to tumour necrosis facto alpha given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD study. *Ann Rheum Dis* 2009; 68: 789-97.
59. SMOLEN J, LANDEWÉ RB *et al.*: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Ann Rheum Dis* 2009; 68: 797-805.
60. NISHIMOTO N, YOSHIZAKI K *et al.*: Toxicity, pharmacokinetics, and dose-finding study of repetitive treatment with the humanized anti-interleukin 6 receptor antibody MRA in rheumatoid arthritis phase I/II clinical study. *J Rheumatol* 2003; 30: 1426-35.
61. JONES G, SEBBA A, GU J *et al.*: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. *Ann Rheum Dis* 2009 Mar 17. [Epub ahead of print].
62. TAN AL, MARZO-ORTEGA H, O'CONNOR P, FRASER A, EMERY P, MCGONAGLE D: Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. *Ann Rheum Dis* 2004; 63: 1041-5.
63. HAIBEL H, RUDWALEIT M, LISTING J, SIEPER J: Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. *Ann Rheum Dis* 2005; 64: 296-8.
64. EDWARDS JCW, SZCZEPANSKI L *et al.*: Efficacy of B cell targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med* 2004; 25: 2572-81.
65. GENOVESE MC, BECKER JC *et al.*: Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med* 2005; 353: 1114-23.